Abbott Laboratories (ABT)
| Market Cap | 231.09B |
| Revenue (ttm) | 42.34B |
| Net Income (ttm) | 13.45B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.70 |
| PE Ratio | 17.25 |
| Forward PE | 25.21 |
| Dividend | $2.36 (1.78%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 9,801,417 |
| Open | 132.17 |
| Previous Close | 130.88 |
| Day's Range | 131.37 - 136.65 |
| 52-Week Range | 99.71 - 141.23 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 140.44 (+5.74%) |
| Earnings Date | Apr 16, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $140.44, which is an increase of 5.74% from the latest price.
News
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease
A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal ...
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concuss...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data f...
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b...
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the ...
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth...
Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ET Company Participants Mike Comilla - VP, IR Robert Ford - Chairman and CEO Phil Boudreau - EVP, Finance and CF...
Nasdaq Down Over 2%; Abbott Laboratories Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 2% on Wednesday.
Abbott Labs sees demand for diabetes products jump, and the stock surges
Abbott Laboratories saw a big jump in demand for its diabetes products in the first quarter, which helped the medical-device company extend its long streak of earnings beats and propelled its stock to...
Abbott Labs Profit Jumps on Gains in Nutrition, Medical Devices
Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.
Abbott Laboratories Stock Slips as First-Quarter Sales Miss Expectations
Abbott Labs posts first-quarter adjusted profit that topped analysts' estimates.
Abbott beats quarterly profit estimate on strong medical device demand
Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 te...
How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings
Abbott Laboratories ABT will release its first-quarter earnings results before the opening bell on Wednesday, April 16.
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve
TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart ...
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy electrica...
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens.
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary In...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...